Lung Cancer

Filters

Online Exclusive

SALE UP TO 25% OFF

Shop The Sale

LuciPral (Pralsetinib) 100mg*120 | Lucius Laos Generic | GLT

Lucius Pharmaceuticals (Lao) — pralsetinib 100mg generic, 120-capsule pack

Regorafenib (Stivarga) 40mg*28's | Bayer Germany Originator | GLT

Bayer Germany originator Stivarga (regorafenib) 40mg 28 tablets for mCRC, GIST & HCC.

Regorafenib (Reganni) 40mg*28's | TLPH Laos Generic | GLT

Reganni — Trans Continental Life Science (TLPH) regorafenib 40mg 28 tablets for mCRC, GIST &...

Regorafenib (LuciRegor) 40mg*28's | Lucius Laos Generic | GLT

LuciRegor — Lucius Pharmaceuticals regorafenib 40mg 28 tablets for mCRC, GIST & HCC.

Lazertinib (Lazcluze) 80/240mg | Janssen US Originator | GLT

Janssen Biotech originator Lazcluze (lazertinib) 80mg & 240mg tablets, third-generation EGFR-TKI for EGFR-mutated NSCLC, US-sourced.

Lazertinib (Leclaza) 80mg | Yuhan Korea Originator | GLT

Yuhan originator Leclaza (lazertinib) 80mg x 84 tablets, the first Korean-developed third-generation EGFR-TKI for NSCLC.

Lazertinib (LuciLazer) 80mg | Lucius Laos Generic | GLT

LuciLazer (lazertinib) 80mg x 60 tablets by Lucius Pharmaceuticals Laos, cost-effective generic third-generation EGFR-TKI.

Pembrolizumab (Keytruda) 100mg/4mL | Japan PMDA-Approved PD-1 Inhibitor | GLT

PD-1 inhibitor for multiple cancers — Japan-sourced, PMDA-approved Keytruda at competitive global pricing

Pembrolizumab (Keytruda) 100mg/4mL & 50mg | US FDA-Approved PD-1 Inhibitor | GLT

PD-1 inhibitor for multiple cancers — US-sourced, FDA-approved Keytruda at competitive global pricing

Pembrolizumab (Keytruda) 100mg/4mL | Hong Kong Registered PD-1 Inhibitor | GLT

PD-1 inhibitor for multiple cancers — Hong Kong-registered Keytruda at competitive global pricing

Pemomab (Pembrolizumab) 100mg/4mL | Affordable PD-1 Inhibitor Biosimilar | GLT

PD-1 inhibitor biosimilar for multiple cancers — cost-effective pembrolizumab at accessible pricing

Kadcyla Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Roche Switzerland Originator | GLT

Roche originator Kadcyla ado-trastuzumab emtansine (T-DM1) 100mg & 160mg vials, HER2-targeted ADC for HER2-positive breast...

UJVIRA Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Zydus India Biosimilar | GLT

Zydus UJVIRA ado-trastuzumab emtansine (T-DM1) biosimilar 100mg & 160mg vials, world's first T-DM1 biosimilar ADC...

Ibtrozi (Taletrectinib) 200mg Capsules | ROS1 Inhibitor | GLT

Nuvation Bio next-generation ROS1 inhibitor for ROS1-positive NSCLC
Sold Out

Braftovi (Encorafenib) 75mg Capsules China | BRAF Inhibitor | GLT

Braftovi (毕太维) encorafenib BRAF V600E inhibitor for metastatic colorectal and lung cancer, Laboratoires Pierre Fabre...
Sold Out

Selpercatinib (Retevmo) 80mg — RET-Driven Cancer | China-Sourced | GLT

NMPA-approved RET inhibitor for RET fusion-positive NSCLC and thyroid cancer (China)
Sold Out

Ceritinib (Spexib) 150mg*150's | Novartis India Originator | GLT

Novartis's Indian-market ceritinib (Spexib) 150mg capsules, 150 per multipack for ALK-positive NSCLC — same originator...
Sold Out

Tagrisso (Osimertinib) 80mg*30 | AstraZeneca UK Originator | GLT

AstraZeneca UK originator osimertinib 80mg — the reference EGFR TKI for NSCLC
Sold Out

Tagrisso (Osimertinib) 80mg*30 | AstraZeneca China NMPA | GLT

China-Mainland Tagrisso 80mg — NMPA-approved, nationally reimbursed originator osimertinib
Sold Out

Ceritinib (Zykadia) 150mg*10's | Novartis Switzerland Originator | GLT

Novartis Switzerland originator Zykadia (ceritinib) 150mg capsules, 10-capsule starter pack for ALK-positive NSCLC.
Sort
  • Recommended
  • Price: Low to High
  • Price: High to Low
  • Newest
  • Best Selling